Delivered by Prof Frances Ruane, Chairperson of the Expert Group on Resource Allocation in the Health Sector, Executive Director of the ESRI at the IPHA Annual Meeting 2010.
the paradigm is changing; the dominant focus for the next decade at least will be value, or to be precise triple value
The Aim is triple value & greater equity
• Allocative value, determined by how the assets are distributed to different sub groups in the population
• Technical value, determined by how well resources are used for all the people in need in the population
• Personalised value, determined by how well the decisions relate to the values of each individual
If you want to see more please look at http://bettervaluehealthcare.weebly.com
March 02, 2018
Value-based health care is one of the most pressing topics in health care finance and policy today. Value-based payment structures are widely touted as critical to controlling runaway health care costs, but are often difficult for health care entities to incorporate into their existing infrastructures. Because value-based health care initiatives have bipartisan support, it is likely that these programs will continue to play a major role in both the public and private health insurance systems. As such, there is a pressing need to evaluate the implementation of these initiatives thus far and to discuss the direction that American health care financing will take in the coming years.
To explore this important issue, the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School collaborated with Ropes & Gray LLP to host a one-day conference on value-based health care. This event brought together scholars, health law practitioners, and health care entities to evaluate the impact of value-based health care on the American health care system.
For more information, visit our website at: http://petrieflom.law.harvard.edu/events/details/will-value-based-care-save-the-health-care-system
the paradigm is changing; the dominant focus for the next decade at least will be value, or to be precise triple value
The Aim is triple value & greater equity
• Allocative value, determined by how the assets are distributed to different sub groups in the population
• Technical value, determined by how well resources are used for all the people in need in the population
• Personalised value, determined by how well the decisions relate to the values of each individual
If you want to see more please look at http://bettervaluehealthcare.weebly.com
March 02, 2018
Value-based health care is one of the most pressing topics in health care finance and policy today. Value-based payment structures are widely touted as critical to controlling runaway health care costs, but are often difficult for health care entities to incorporate into their existing infrastructures. Because value-based health care initiatives have bipartisan support, it is likely that these programs will continue to play a major role in both the public and private health insurance systems. As such, there is a pressing need to evaluate the implementation of these initiatives thus far and to discuss the direction that American health care financing will take in the coming years.
To explore this important issue, the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School collaborated with Ropes & Gray LLP to host a one-day conference on value-based health care. This event brought together scholars, health law practitioners, and health care entities to evaluate the impact of value-based health care on the American health care system.
For more information, visit our website at: http://petrieflom.law.harvard.edu/events/details/will-value-based-care-save-the-health-care-system
Recent advances in the evidence base for technology-based behavioral health applications have provided clinicians a better understanding and guidance on the integration of these tools into clinical care. Participants will learn about research findings on current technologies in use in clinical practice, such as audio conferencing, video conferencing, and virtual reality, in addition to tools available for use between patients, such as the use of websites and mobile applications and wearable sensors.
Evaluating the priority setting processes used across the Cochrane Collaborationmonalisa2n
A workshop in Cochrane Colloquium, Freiburg, Germany Oct 2008 on Ensuring relevance and building enthusiasm for Cochrane reviews:
determining appropriate methods for identifying priority topics for future Cochrane reviews
Patient Centered Medical home talk at WVUPaul Grundy
To employers the cost of healthcare is now a business issue and this talk is about what one large buyer IBM did to drive transformation via broad coalition with other large employers to form the Patient Centered Medical Home movement and the covenant between buyer and provider away from the garbage we now buy episodic uncoordinated disintegrated care. In the change of convenient conversation we have worked with the Primary care providers to give us coordinated, integrated, accessible and compressive care with a set of principles know as the Patient centered medical home.
A Patient Centered Medical Home (PCMH) happens when primary care healers keeping that core healing relationship with their patients step up to become specialists in Family and Community Medicine. The move is to the discipline of leading a team that delivers population health management, patent centered prevention, care that is coordination, comprehensive accessible 24/7 and integrated across a deliver system. PCMH happens when the specialists in Family and Community Medicine wake up every morning and ask the question how will my team improve the health of my community today?
All over the world three huge factors are in play that is driving the concept of Patient Centered Medical Home. They are:
1) Cost and demography
2) Information technology and data (information that is actionable will equal a demand for accountability by the payer or buyer of the care)
3) Consumer demand to engage healthcare differently (at least as well as they can their bank- on line) have a question about lab results why not e-mail?
But at its core it is a move toward integration of a healing relationship in primary care and population management all at the point of care with the tools to do just that.
discussion on Health Economics and Health Care in our country and abroad, and what resources are given by the private sectors and with the very scarce help from the DOH, national and local government, and from the support given by WHO.
Population Health Management: Where are YOU?Phytel
This presentation explains how population health is fundamental to value-based delivery models, including key principles and definitions of PHM, as well as how to assess your organization’s “population health readiness.”
To lower health costs, physician networks and medical homes must employ a closed loop population management program that focus on patient SOH stratification, chronic disease management, care coordination and incentive management. This approach will enable them to consistently reduce ER and inpatient admissions, which are the greatest expenditures in health care today.
Jacquie White, Deputy Director of NHS England Long Term Conditions, Older People & End of Life Care and Claire Cordeaux SIMUL8 Executive Director for Health & Social Care were invited by Centers for Medicare & Medicaid Services to discuss how NHS England work in chronic disease.
Recent advances in the evidence base for technology-based behavioral health applications have provided clinicians a better understanding and guidance on the integration of these tools into clinical care. Participants will learn about research findings on current technologies in use in clinical practice, such as audio conferencing, video conferencing, and virtual reality, in addition to tools available for use between patients, such as the use of websites and mobile applications and wearable sensors.
Evaluating the priority setting processes used across the Cochrane Collaborationmonalisa2n
A workshop in Cochrane Colloquium, Freiburg, Germany Oct 2008 on Ensuring relevance and building enthusiasm for Cochrane reviews:
determining appropriate methods for identifying priority topics for future Cochrane reviews
Patient Centered Medical home talk at WVUPaul Grundy
To employers the cost of healthcare is now a business issue and this talk is about what one large buyer IBM did to drive transformation via broad coalition with other large employers to form the Patient Centered Medical Home movement and the covenant between buyer and provider away from the garbage we now buy episodic uncoordinated disintegrated care. In the change of convenient conversation we have worked with the Primary care providers to give us coordinated, integrated, accessible and compressive care with a set of principles know as the Patient centered medical home.
A Patient Centered Medical Home (PCMH) happens when primary care healers keeping that core healing relationship with their patients step up to become specialists in Family and Community Medicine. The move is to the discipline of leading a team that delivers population health management, patent centered prevention, care that is coordination, comprehensive accessible 24/7 and integrated across a deliver system. PCMH happens when the specialists in Family and Community Medicine wake up every morning and ask the question how will my team improve the health of my community today?
All over the world three huge factors are in play that is driving the concept of Patient Centered Medical Home. They are:
1) Cost and demography
2) Information technology and data (information that is actionable will equal a demand for accountability by the payer or buyer of the care)
3) Consumer demand to engage healthcare differently (at least as well as they can their bank- on line) have a question about lab results why not e-mail?
But at its core it is a move toward integration of a healing relationship in primary care and population management all at the point of care with the tools to do just that.
discussion on Health Economics and Health Care in our country and abroad, and what resources are given by the private sectors and with the very scarce help from the DOH, national and local government, and from the support given by WHO.
Population Health Management: Where are YOU?Phytel
This presentation explains how population health is fundamental to value-based delivery models, including key principles and definitions of PHM, as well as how to assess your organization’s “population health readiness.”
To lower health costs, physician networks and medical homes must employ a closed loop population management program that focus on patient SOH stratification, chronic disease management, care coordination and incentive management. This approach will enable them to consistently reduce ER and inpatient admissions, which are the greatest expenditures in health care today.
Jacquie White, Deputy Director of NHS England Long Term Conditions, Older People & End of Life Care and Claire Cordeaux SIMUL8 Executive Director for Health & Social Care were invited by Centers for Medicare & Medicaid Services to discuss how NHS England work in chronic disease.
Resource estimation and allocation happens to be one of the most crucial make/break points for most projects. However, this detail usually gets underestimated by project managers which consequently become evident in their lack of efficiency and effectiveness in the tasks they oversee. This lecture brings out a few techniques (scientific) as to how PMs can easily navigate their way through this difficulty.
Soraya Ghebleh - Using Financial Incentives to Influence Clinical Decision Ma...Soraya Ghebleh
This slide deck discusses some of the relevant factors that should be considered when designing financial incentives for providers of healthcare services.
OHE Lecturing for Professional Training at International Centre of Parliament...Office of Health Economics
On 7th November 2018, Bernarda Zamora delivered a pro bono lecture to professionals from diverse countries enrolled at the Professional Certificate in Strategic Planning organised by the International Centre of Parliamentary Studies.
Author(s) and affiliation(s): Bernarda Zamora, Office of Health Economics
Conference/meeting: Professional Certificate in Strategic Planning organised by the International Centre of Parliamentary Studies
Location: Conference Centre, London
Date: Conference Centre, London
Presented at “Financial Protection and Improved Access to Health Care: Peer-to-Peer Learning Workshop Finding Solutions to Common Challenges” in Accra, Ghana, February 2016. To learn more, visit: https://www.hfgproject.org/ghana-uhc-workshop
Similar to How to ensure the best utilisation of healthcare resources in Ireland - the economist perspective (20)
Delivered by Mr David Gallagher, IPHA President, at the IPHA Annual Meeting 2010 during the Session entitled "Ensuring the best health outcomes for Irish patients while securing value for money".
Delivered by Dr Michael Barry, National Centre for Pharmacoeconomics at the IPHA Annual Meeting 2010 during the Session entitled "Ensuring the best health outcomes for Irish patients while securing value for money".
Delivered by Dr Colin Doherty, Epilepsy Clinical Lead, Health Service Executive at the IPHA Annual Meeting 2010 during the Session entitled "Ensuring the best health outcomes for Irish patients while securing value for money".
Pharmaceutical Healthcare Facts and Figures 2010 provides detailed facts and figures about healthcare in Ireland and the pharmaceutical and healthcare industry both nationally and globally across the following areas: Healthcare Today, Self-Care Today, Demographic Trends, Healthcare Tomorrow, The Medicines Industry, Medicines in the Community and Medicines and Global Health.
Presentation delivered by Dr Kathleen Bennett, Department of Pharmacology and Therapeutics, Trinity Centre for Health Sciences, St James’s Hospital at the Irish Pharmaceutical Healthcare Association Meeting 2009.
Presentation delivered by Mr Shaun Flanagan, Corporate Pharmaceutical Unit, Health Service Executive at the Irish Pharmaceutical Healthcare Association Annual Meeting 2009.
Presentation delivered by Dr Eibhlin Connolly, Deputy Chief Medical Officer at the Department of Health and Children at the Irish Pharmaceutical Healthcare Association Annual Meeting 2009.
IPHA Healthcare Facts and Figures provides detailed facts and figures about healthcare in Ireland and the pharmaceutical and healthcare industry both nationally and globally across the following areas: Healthcare Today, Self-Care Today, Demographic Trends, Healthcare Tomorrow, The Medicines Industry, Medicines in the Community and Medicines and Global Health
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stockrebeccabio
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Telegram: bmksupplier
signal: +85264872720
threema: TUD4A6YC
You can contact me on Telegram or Threema
Communicate promptly and reply
Free of customs clearance, Double Clearance 100% pass delivery to USA, Canada, Spain, Germany, Netherland, Poland, Italy, Sweden, UK, Czech Republic, Australia, Mexico, Russia, Ukraine, Kazakhstan.Door to door service
Hot Selling Organic intermediates
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
How to ensure the best utilisation of healthcare resources in Ireland - the economist perspective
1. Improving Resource Allocation in
the Irish Health Sector –
Some New Insights
Presentation to IPHA Conference on
Enterprise and Health Solutions for
Irish Patients and the Irish Economy
25 November 2010
Frances Ruane, ESRI
2. Outline of Presentation
Context: Expert Group Report which sought to
develop resource allocation and financing
systems that support better health and better
health services
Approach of the Expert Group
Characterisation of the Systemic Issues
Today’s system failures
Guiding Principles for the future
Key Recommendations
3. Better health through better health
services
Focus on health and wellbeing requires
The right services delivered by the right skills and facilities
in the right places
Fairness, equity and focus on greatest needs
Sustainable and efficient
Joined up and fit for purpose
All of these are stated objectives of Irish health policy
How do we do better at achieving them?
Perspective: clinical, managerial, economic, administrative
7. Expert Group Methodology
Gathered international* evidence on best
practice and sought local submissions
Focus on integrated care: chronic disease
Analysed stated health policy in Ireland
Derived Guiding Principles
Compared current arrangements with Guiding
Principles to identify failures systematically
Systemic Approach: Aim to change how
things work so that individuals are supported
10. Current Systemic Failures [1]
Planning Vacuum
No integration of capital/current expenditure
No whole system analysis [public/private]
No rational basis for national planning
Focus on fiscal rather than total health cost
Incentives out of line with stated objectives
Incentives to use hospital care
No rewards for improvements in efficiency/safety
No governance structures / budgeting processes to
locate service delivery in the appropriate setting
11. Current Systemic Failures [2]
Financing
Unregulated GPs [fees/quality] for majority
Access to care overly related to ability to pay
Widespread anomalies in what/who is covered
Continuing issues with consultant contract
Sustainability
GP contract is totally inappropriate
Pharmacy / GP charges are comparatively high
Prescription rates have risen dramatically
Little use of techniques to improve sustainability
12. What are the Guiding Principles? [1]
Money should follow need not history
Policy and entitlements should be set nationally,
and delivered locally
We should fund activity not organisations
We should support integrated, safe, cost-
effective sustainable care in the best settings –
focus on Chronic Disease requires integrated
system.
13. Primary Care Acute Hospital
Care
Community and
Continuing
Care
Is this the current system?
17. What are the Guiding Principles? [2]
Financial incentives should:
a) encourage providers to meet priorities and quality
standards set in policy at minimum cost
b) encourage users to use the appropriate services
People should pay according to their incomes
and have access according to their needs
Arrangements should be sustainable.
18. Resource Allocation Recommendations:
Systems
Strengthen planning frameworks / processes
Distribute resources based on real population need
Deliver locally within national frameworks and
strengthened management – not => health boards!
Pay providers for what they deliver at (case-mix
adjusted) prices that reflect efficient delivery.
19. Resource Allocation Recommendations:
Delivery
Strengthen clinical protocols to manage major
diseases fairly and efficiently
Develop and strengthen primary/community
services and shift services from hospitals to
community where appropriate
Guarantee rights to timely care – NTPF approach to
apply to all HSE funding – phase out current NTPF
role on waiting lists.
20. Financing Recommendations
Less pay as you go, more prepaid
Fairer and clearer entitlements
Increase transparency of flows to providers
Replace tax reliefs on medical expenses and
private insurance with more targeted subsidies*
Lower and fairer user fees for GP services and
drugs, based on income and health status
21. Sustainability Recommendations
Measures to improve information
More fit-for-purpose contracts
More evaluation of drugs and treatments
Improved cost control
Better regulation and performance management
Better capital planning.
Major changes for: DoHC, HSE, Hospital Care,
Primary Care, Community & Continuing Care
22. Relevance of the Report to Pharma Sector
Focus on Health and Health care
Focus on moving to new models of care
Focus on Chronic Disease Management – and
making sure that resources support it
Focus on care provision outside institutions
Focus on value for money and efficiency linked to
high standards [clinical protocols]
Focus on sustainability – keeping down unit costs
Specific recommendations
23. Specific Recommendations [1]
Evaluation of all high-cost, high-use drugs on
the current GMS/DP lists, based on Irish costs
and international experience of their outcomes
HSE and DoHC engage immediately in the
development of official guidelines and clinical
protocols on the use of new technologies
Develop reference pricing
Review choice of comparator countries used for
setting ex-factory price of pharmaceuticals
Extend tendering for sole supply contracts for
additional pharmaceutical products
24. Specific Recommendations [2]
Establish treatment and prescribing protocols that
promote the use of generics
Introduce regulations to mandate that all prescriptions
for public and private patients must contain the
generics name so the drug prescribed
Introduce regulations to mandate all pharmacists to
dispense the lowest cost version of the drug unless the
patient specifically request a particular brand and is
willing to pay the additional cost
Extend information on generics more widely among
doctors, pharmacists and patients
27. What will change for C&C* Care
Before
~ Historic budgets
Uneven resources
Weak infrastructure
Weak links to HC*/PC*
Overlap of purchasers
and providers
After
Prospective funding
Pop. health budgets
Improved infrastructure
Systemic links to HC/PC
Move to separate
purchasers/providers
*C&C = Community and Continuing Care; HC = Hospital Care; PC = Primary Care
28. What will change for the DoHC?
Before
Fragmented Policy
Framework
Resource usage policy
oriented towards public
health-care system
Lack of multi-annual
capital/current system
planning
Unclear boundary with
HSE in relation to
resource allocation
After
Integrated Policy
framework
Resource usage policy
covers total health-care
system
Five-year planning
framework to cover all
health-care spend
Clarity with respect to
resource allocation roles
of DoHC and HSE
29. What will change for the HSE?
Before
Integration of HSE roles as
purchaser & provider
Separate budgeting for
hospitals / PCCC*
Separate structures for
resource allocation,
management and clinical
leadership
Targeted waiting times
After
Planned move to
purchaser/provider split
Integrated budgeting for all
sectors
Integrated leadership
across resource allocation,
management and clinical
standards
Guaranteed waiting times
*PCCC = Primary, Continuing and Community Care:
30. What will change for Hospitals?
Before
Mostly Block Grant
Inefficiency unknown
Budgets supporting silo
work practices
Large barriers between
hospitals and other care
settings
After
Prospective funding
Efficiency rewarded
Budgets promoting team-
based approach
Resources linking
hospitals and other care
settings
31. What will change for the Patient?
Before
Unplanned eligibility
patterns
GP/Drug payments not
related to incomes and
need / charge rates
unregulated
Fragmented care –
people getting services
they do not need and
lacking those they need.
After
Clear eligibility related to
need
GP/Drug payments
related to income and
need – tiered medical
card for all
Individual care pathways
– crucial for caring for the
ageing population